drugset / Trial / NCT02724618
Nanocurcumin for Prostate Cancer Patients Undergoing Radiotherapy (RT)
Phase 2
Unknown
64 enrolled
Shahid Beheshti University of Medical Sciences
Behnam Daheshpour Charity Organization, Tehran, Iran · collab
RandomizedParallel-groupQuadruple-blindSupportive care
Summary
There is a growing body of evidence exploring the role of curcumin as a radioprotector against radiation-induced injury in normal tissues as well as a radiosensitizer in tumor cells. The aim of this study is to determine the efficacy of oral nanocurcumin in prostate cancer patients undergoing radiotherapy.
Timeline
- Start
- 2016-03
- Primary completion
- 2017-04-15
- Completion
- 2022-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Curcumin | Small molecule | 120 mg | Oral |